HRS 5965
Alternative Names: HRS-5965Latest Information Update: 17 Jul 2024
At a glance
- Originator Chengdu Suncadia Medicine
- Class Anti-inflammatories; Urologics
- Mechanism of Action Complement factor B modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Paroxysmal nocturnal haemoglobinuria
- Phase I Glomerulonephritis
Most Recent Events
- 08 Jul 2024 Chengdu Suncadia Medicine plans a phase I trial (In volunteers, In adults) (PO, Capsule) (PO. Tablet) in July 2024 (NCT06490991)
- 06 Feb 2024 Chengdu Suncadia Medicine initiates a phase II trial in Paroxysmal nocturnal hemoglobinuria in China (PO)(NCT06238544)
- 02 Feb 2024 Chengdu Suncadia Medicine plans a phase II trial in Paroxysmal nocturnal hemoglobinuria (Treatment-experienced) (PO, Tablet) in February 2024 (NCT06238544)